Human C5b-9 Terminal Complement Complex / TCC

Mouse

Human (tested or 100% immunogen sequence identity)

IgG2a Monoclonal

3R2/0

Unconjugated

Affinity purified

Unmodified

Recognizes the SC5b-9 complex of around 330 kD. Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kD C5b which is bound to cells via 71 kD C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kD S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is therefore a reliable indicator of terminal complement pathway activation. Removal of Sodium Azide is recommended prior to use in functional assays. Reported to work in western blotting applications.

• IHC
• IHC - Frozen
• Western blot
• Flow Cytometry
• ELISA

BBS, 0.1% Sodium Azide

Store at 4°C or at -20°C. Store undiluted. Avoid freeze-thaw cycles. Microcentrifugation recommended if solution contains precipitate.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.